TY - JOUR
T1 - Everolimus Personalized Therapy
T2 - Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
AU - Masuda, Satohiro
AU - Lemaitre, Florian
AU - Barten, Markus J.
AU - Bergan, Stein
AU - Shipkova, Maria
AU - van Gelder, Teun
AU - Vinks, Sander
AU - Wieland, Eberhard
AU - Bornemann-Kolatzki, Kirsten
AU - Brunet, Mercè
AU - de Winter, Brenda
AU - Dieterlen, Maja Theresa
AU - Elens, Laure
AU - Ito, Taihei
AU - Johnson-Davis, Kamisha
AU - Kunicki, Pawel K.
AU - Lawson, Roland
AU - Lloberas, Nuria
AU - Marquet, Pierre
AU - Millan, Olga
AU - Mizuno, Tomoyuki
AU - Moes, Dirk Jan A.R.
AU - Noceti, Ofelia
AU - Oellerich, Michael
AU - Pattanaik, Smita
AU - Pawinski, Tomasz
AU - Seger, Christoph
AU - van Schaik, Ron
AU - Venkataramanan, Raman
AU - Walson, Phil
AU - Woillard, Jean Baptiste
AU - Langman, Loralie J.
N1 - Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2025/2/1
Y1 - 2025/2/1
N2 - The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
AB - The Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology established the second consensus report to guide therapeutic drug monitoring (TDM) of everolimus (EVR) and its optimal use in clinical practice 7 years after the first version was published in 2016. This version provides information focused on new developments that have arisen in the last 7 years. For the general aspects of the pharmacology and TDM of EVR that have retained their relevance, readers can refer to the 2016 document. This edition includes new evidence from the literature, focusing on the topics updated during the last 7 years, including indirect pharmacological effects of EVR on the mammalian target of rapamycin complex 2 with the major mechanism of direct inhibition of the mammalian target of rapamycin complex 1. In addition, various concepts and technical options to monitor EVR concentrations, improve analytical performance, and increase the number of options available for immunochemical analytical methods have been included. Only limited new pharmacogenetic information regarding EVR has emerged; however, pharmacometrics and model-informed precision dosing have been constructed using physiological parameters as covariates, including pharmacogenetic information. In clinical settings, EVR is combined with a decreased dose of calcineurin inhibitors, such as tacrolimus and cyclosporine, instead of mycophenolic acid. The literature and recommendations for specific organ transplantations, such as that of the kidneys, liver, heart, and lungs, as well as for oncology and pediatrics have been updated. EVR TDM for pancreatic and islet transplantation has been added to this edition. The pharmacodynamic monitoring of EVR in organ transplantation has also been updated. These updates and additions, along with the previous version of this consensus document, will be helpful to clinicians and researchers treating patients receiving EVR.
KW - everolimus
KW - mTOR inhibitor
KW - oncology
KW - therapeutic drug monitoring
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85206293038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206293038&partnerID=8YFLogxK
U2 - 10.1097/FTD.0000000000001250
DO - 10.1097/FTD.0000000000001250
M3 - Review article
C2 - 39331837
AN - SCOPUS:85206293038
SN - 0163-4356
VL - 47
SP - 4
EP - 31
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 1
ER -